We did not observe any consistent correlation of CD38 expression and anti-leukemic efficacy of daratumumab; only in primary AML cells co-cultured with HUVECs in the presence of ATRA the anti-leukemic activity of daratumumab depended on CD38 expression. This evidence concerns the gene CD38 and acute myeloid leukemia.